A Canadian, multicenter, double-blind, randomized, parallel-group study of the safety, tolerability, and efficacy of treatment with higher doses of quetiapine fumarate (Seroquel (R)) greater than 800 mg/day in schizophrenic or schizoaffective subjects.

Trial Profile

A Canadian, multicenter, double-blind, randomized, parallel-group study of the safety, tolerability, and efficacy of treatment with higher doses of quetiapine fumarate (Seroquel (R)) greater than 800 mg/day in schizophrenic or schizoaffective subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2011

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2009 Actual end date (1 Sep 2005), trial phase changed from IV to III and planned patient number (330) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2009 New source identified and integrated (ClinicalTrials.gov.)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top